Kyorin Pharmaceutical and Dainippon Sumitomo Halt Gatiflo Sales
This article was originally published in PharmAsia News
Tokyo based Kyorin Pharmaceutical and Dainippon Sumitomo voluntarily stopped selling oral antibioticGatiflo (gatifloxacin) Sept. 30. U.S. FDA removed gatifloxacin from its approved drug list due to serious side effects such as abnormal blood glucose levels. Manufactured by Kyorin and marketed by Dainippon Sumitomo, gatifloxacin is an oral antibiotic to treat pneumonia and other infections. Kyorin estimates the move will not negatively affect patients as there are many alternatives from other companies. The drug has been administrated to 14.7 million patients in Japan and the two companies reported ¥3.5 billion in Gatiflo sales last year. (Click here for more - Japanese language)
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.